Search Results
May 06, 2026, 08:30 ET Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women
(Atossa or the Company) (Nasdaq: ATOS), a clinical-stage biopharmaceutical company focused on developing novel therapies targeting breast cancer and rare diseases, today announced the publication of results from the KARISMA Endoxifen trial in the Journal of the National Cancer Institute (JNCI). The randomized,
More news about: Atossa Therapeutics Inc
May 06, 2026, 08:30 ET EverSmith Brands Appoints Second-Generation Franchise Leader John Dobelbower as Senior Vice President of Growth & Development
his father's old stomping grounds, where he helped scale multiple brands and refine his expertise in multi-brand platform growth."John brings a rare combination of lived experience, strategic discipline and operational insight," said Justin Ghadery, Chief Executive Officer of EverSmith Brands. "He
More news about: EverSmith Brands
May 06, 2026, 08:30 ET Tortuga Growth Partners Expands Healthcare Investment Strategy; Appoints Michael O'Neil as Operating Partner
Michael as we continue to deploy capital into the healthcare technology sector," said Ashray Prasad, Managing Member at Tortuga Growth Partners. "His rare combination of serial entrepreneurship, deep operating knowledge, and network within health systems will complement our disciplined buy-and-build approach
More news about: Tortuga Growth Partners
May 06, 2026, 08:30 ET Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia
the terms of the Creative Commons CC BY licenseAbout Congenital Adrenal HyperplasiaCongenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal
More news about: Neurocrine Biosciences, Inc.
May 06, 2026, 08:15 ET Metallium Announces Contracts for 50% of Stage-1 Printed Circuit Board Feedstock Target
The company's patented Flash Joule Heating (FJH) technology enables the extraction of high-value materials, including gallium, germanium, antimony, rare earth elements, and gold, from feedstocks such as refinery scrap, e-waste and monazite. The company's secured its first commercial site in Texas via
More news about: Metallium Ltd.
May 06, 2026, 08:03 ET Storyteller Overland Announces Leadership Transition to Accelerate Next Phase of Growth
friend and deeply values-aligned business partner, Neil Grimmer, as Storyteller's next CEO. As any business builder or founder will tell you, it is a rare blessing to have such ease in making a transition like this. But after working closely with Neil as our Chief Strategy Officer to elevate so many aspects
More news about: Storyteller Overland
May 06, 2026, 08:00 ET Invicti Appoints Katie Bullard to Board of Directors to Support Next Phase of Growth
ZoomInfo and Red Canary through expansion will help Invicti strengthen GTM focus, execution, and capitalize on market opportunities."Katie brings a rare combination of operational rigor and go-to-market leadership that is critical at this stage of our journey," said Neil Roseman, CEO of Invicti. "As
More news about: Invicti Security
May 06, 2026, 08:00 ET Nobu Hospitality to Launch Hotel, Restaurant and Residences Across 185 Acres in Rutland, England
vision of creating something genuinely special, a place where the magic of Nobu can be experienced in a peaceful rural setting, offering something rare, memorable, and deeply personal for everyone who visits." The project reflects continued demand for experience-led destinations that combine
More news about: Nobu Hospitality
May 06, 2026, 08:00 ET Nobu Hospitality to Launch Hotel, Restaurant and Residences Across 185 Acres in Rutland, England
vision of creating something genuinely special, a place where the magic of Nobu can be experienced in a peaceful rural setting, offering something rare, memorable, and deeply personal for everyone who visits." The project reflects continued demand for experience-led destinations that combine
More news about: Nobu Hospitality
May 06, 2026, 08:00 ET Nobu Hospitality lance un hôtel, un restaurant et des résidences sur 185 acres à Rutland, en Angleterre
vision de créer quelque chose de vraiment spécial, un lieu où la magie de Nobu peut être vécue dans un cadre rural paisible, offrant quelque chose de rare, de mémorable et de profondément personnel à tous ceux qui le visitent". Le projet reflète la demande constante de destinations axées sur
More news about: Nobu Hospitality
May 06, 2026, 08:00 ET Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program
precision dermatology. The Company's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome may be fatal in infancy with those living beyond a year having profound
More news about: Azitra, Inc.
May 06, 2026, 07:05 ET REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy
Board Certified Neurologist and Neuromuscular Physician, Founder and Director Neurology and Neuromuscular Care Center and Founder and Director Neurology Rare Disease Center.The company will also report financial results and operational highlights for the first quarter ended March 31, 2026 pre-market
More news about: REGENXBIO Inc.
May 06, 2026, 07:00 ET Defense Metals Announces Commencement of the Spring 2026 Drill Program at Wicheeda Rare Earths Project
Company, who is a "Qualified Person" as defined in NI 43-101.About Defense Metals Corp. and the Wicheeda Rare Earth Element ProjectDefense Metals Corp. is an advanced rare earth elements ("REE") development company focused on delivering strategically critical metals to the western world
More news about: Defense Metals Corp.
May 06, 2026, 06:50 ET Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
(NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended March 31, 2026 and provide a
More news about: Protalix BioTherapeutics, Inc.
May 06, 2026, 06:30 ET Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations
to maturity; fluctuations in currency exchange rates and interest rates; receipt of potential earnout payments in connection with the sale of the HRA Rare Diseases Business and the risk that potential costs or liabilities incurred or retained in connection with this transaction may exceed our estimates
More news about: Perrigo Company plc
May 06, 2026, 06:21 ET Bulletin from Sobi's Annual General Meeting (AGM)
sobi.com.Sobi®Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 2,000 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK
More news about: Swedish Orphan Biovitrum AB
May 06, 2026, 06:17 ET Bulletin from Sobi's Annual General Meeting (AGM)
sobi.com.Sobi®Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 2,000 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK
More news about: Swedish Orphan Biovitrum AB
May 06, 2026, 06:01 ET Vermilion Energy Inc. Reports Strong Q1 2026 Operational and Financial Results and Continued Debt Reduction
in February 2026, and a subsequent shut-in due to Cyclone Narelle in late March 2026. Experiencing two cyclones events in one quarter is extremely rare, and our teams successfully managed all aspects of the safe shut-in of operations and evacuation of personnel before returning to the platform to initiate
More news about: Vermilion Energy Inc.
May 06, 2026, 06:00 ET No Traffic Lights, Just Paradise: Why NYT Named Camiguin a 'Must-Visit' in 2026
imagination of travelers seeking serenity, adventure, and authentic local experiences. Praised for its "zero traffic lights" charm, the island promises a rare combination of unspoiled natural beauty and easy accessibility.
More news about: Department of Tourism Philippines
May 05, 2026, 22:11 ET New Book Revives the Story of a Radio Pioneer and a Disputed Chapter in Innovation History
recognition, and he wanted to let the world know it.""The Standby" combines personal narrative with historical documentation, offering readers a rare, insider perspective on the formative years of modern communications technology, sharing new context about the individuals and innovations that helped
More news about: Archway Publishing
May 05, 2026, 20:42 ET Rare Shades 7 presentado por 000 Media agrega un estudio de los autos deportivos Porsche en colores inusuales en un lugar extraordinario durante el Festival NYCxDESIGN
Studios y eventos anteriores de Rare Shades si lo desea.Rare Shades 7 16 de mayo de 2026, de 1:00 p. m. a 6:00 p. m.Wildflower Studios, 35-15 19th Avenue, Queens, Nueva York 11105Entradas disponibles en 000magazine.com/pages/rare-shades-nycAbout
More news about: 000 Magazine
May 05, 2026, 19:09 ET Rare Shades 7 presented by 000 Media adds study of Porsche sports cars in unusual colors at an extraordinary venue during NYCxDESIGN Festival
while Rare Shades 6 took place at the Aga Khan Museum in Toronto. This year's venue in New York City will be an integral part of the Rare Shades 7 experience."Wildflower Studios was designed to enable storytelling at the highest level," said Adam Gordon, cofounder of Wildflower Studios. "Rare Shades
More news about: 000 Magazine
May 05, 2026, 17:01 ET Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1
Kingdom, as well as Swissmedic approval in March 2026.4,5 This milestone further reflects Norgine's ability to navigate regulatory pathways for rare and specialist medicines.PEDMARQSI® is not currently included on the Pharmaceutical Benefits Scheme (PBS).Please refer to
More news about: Norgine
May 05, 2026, 17:01 ET Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1
Kingdom, as well as Swissmedic approval in March 2026.4,5 This milestone further reflects Norgine's ability to navigate regulatory pathways for rare and specialist medicines.PEDMARQSI® is not currently included on the Pharmaceutical Benefits Scheme (PBS).Please refer to
More news about: Norgine
May 05, 2026, 17:00 ET CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
results in a Phase II clinical study of ifetroban in patients with cardiomyopathy associated with Duchenne muscular dystrophy ("DMD"). This rare, fatal genetic neuromuscular disease results in deterioration of the skeletal, heart and lung muscles. Discussions with the FDA are underway regarding
More news about: Cumberland Pharmaceuticals Inc.